AVA.ASX XRG.ASX CU6.ASX CHL.ASX RMD.ASX

Market Roundup: Ava Risk, xReality, Clarity Pharma, Camplify, and Resmed Shine in Q2

Ava Risk Group Secures Strategic Investment, Forecasts Strong H2 Ava Risk Group (ASX: AVA) provided an update on its Q2 FY2026 trading performance. While H1 revenue fell short of guidance due to delayed orders, the company expects a significant improvement in H2, forecasting revenue of $23.0 to $26.0 million. This would result in full-year revenue of $37.0 to $40.0 million. Ava Risk also announced a strategic investment of up to $12.6 million from Hale Capital, which will support the company's growth initiatives and US expansion.

xReality Group Delivers Record Cash Receipts and Customer Growth xReality Group Ltd (ASX: XRG) reported its strongest quarterly performance to date, with record cash receipts of $7.4 million in Q2 (up 85% QoQ) and $11.4 million year-to-date (up 20% PcP). The company's Operator XR division saw continued strong performance, with total contract value up 23% QoQ and annual recurring revenue up 28% year-to-date. xReality also expanded its leadership team and secured a new headquarters to support future growth.

Clarity Pharma Advances Prostate Cancer and NET Programs, Bolsters Balance Sheet Clarity Pharmaceuticals (ASX: CU6) remains well-funded with a cash position of $226.2 million, providing a strong balance sheet to progress its innovative radiopharmaceutical products. The company reported positive interim data from the SECuRE trial for its lead prostate cancer product, 67Cu-SAR-bisPSMA, and announced plans to commence a pivotal Phase III trial for 64Cu-SARTATE in neuroendocrine tumors.

Camplify Holdings Manages Costs, Provisions for European Insurance Expenses Camplify Holdings Ltd (ASX: CHL) released its Q3 FY2026 Appendix 4C, highlighting reduced operating costs and membership revenue. The company has identified a $1.8 million accrual for unbudgeted insurance expenses in its European operations, as well as a $1.3 million contingency for policy performance related to loss-sharing provisions.

Resmed Delivers Double-Digit Growth, Margin Expansion in Q2 Resmed Inc. (ASX: RMD) reported strong Q2 FY2026 results, with revenue increasing 11% to $1.4 billion and gross margin expanding by 320 basis points to 61.8%. Income from operations rose 18%, driven by robust demand for the company's sleep and respiratory care devices and digital health ecosystem. Resmed provided guidance for fiscal year 2026, including revenue growth of 9-11% and non-GAAP EPS growth of 15-17%.